Recent advances in managing triple-negative breast cancers.
Triple-negative breast cancer (TNBC) has been recently recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach compared with other breast cancer subgroups. Because TNBC is defined by the absence of a target (either hormone receptors or HER-2), conventional cytotoxic therapy is still the mainstay of treatment. This report focuses on the current state and recent advances in managing TNBC.
Division of Medical Oncology, Department of Oncology, Hematology and Respiratory Diseases, University Hospital, University of Modena and Reggio Emilia Via del Pozzo, 71 - 41100, Modena Italy.
Carmelo
C
Bengala